Training activity information
Details
Analyse, interpret and draft a clinical report for the detection of MRD monitoring for two of the following:
- BCR-ABL
- PML-RARA
- CBFB-MYH11
- RUNX1-RUN1T1
- IGH/TR
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Considerations
- Principles of the molecular testing strategy and process
- IQC and EQA
- Best practice guidelines for reporting, including recommendations for patient treatment and management, follow up, further testing or clinical trials, if relevant
- Correct scientific and clinical terminology, including HGVS nomenclature
- Communication of complex scientific information to the multidisciplinary team
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 4 |
Outcome
Analyse, interpret and prepare interpretive reports for common haematological malignancies, including results for somatic variants, kinase domain mutations, minimal residual disease and post-transplant monitoring. |
| # 5 |
Outcome
Interpret the associated IQC and EQA of the laboratory tests for investigation of haematological malignancies. |
| # 6 |
Outcome
Practice with the relevant specialities for the diagnosis, monitoring and management of haematological malignancies. |